During tumor progression, molecules produced by immune and cancer cells, such as IL-4, CSF1, and TGF-β, contribute to the switch of TAMs to the alternative M2 phenotype-producing anti-inflammatory and proangiogenic molecules, such as IL-10, arginase 1, TGF-β, and vascular growth factor (VEGF) supporting the tumor growth [4]. The gene discussed is TGFB1; the disease is cancer.